Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Conjunctivitis Treatment Market

Conjunctivitis Treatment Market Trends

Report ID: GMI8377
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Conjunctivitis Treatment Market Trends

Ongoing research and technological advancements in the field of conjunctivitis treatment are focused on improving diagnostic accuracy and enhancing therapeutic outcomes. These advancements underscore the continuous progress in the field of ophthalmology, providing healthcare professionals with innovative tools to diagnose and treat conjunctivitis more effectively.

Recent advancements in eye drops for treating conjunctivitis have leveraged technology to enhance efficacy and patient outcomes. For instance, development of antibiotic eye drops, which containing polymyxin B, bacitracin, and erythromycin are commonly used to treat bacterial conjunctivitis. The choice of antibiotic depends on the severity of the infection, the patient's age, and any underlying medical conditions.
Additionally, ongoing research is looking into the use of artificial tears, antihistamines, and lubricating eye drops for alleviating symptoms associated with different types of conjunctivitis. For example, researchers are studying the use of artificial tears to alleviate dryness and discomfort associated with conjunctivitis. Additionally, examining the use of antihistamines to control itching and inflammation associated with allergic conjunctivitis. These developments may improve the overall management of conjunctivitis by providing quicker and more effective symptomatic relief.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of conjunctivitis treatment reached USD 4.1 billion in 2023 and is set to cross USD 6.3 billion by 2032, owing to the rising prevalence of conjunctivitis from viral outbreaks, bacterial infections, allergies, environmental influences, and increased global travel worldwide.

The anti-allergic segment is expected to reach USD 4.1 billion by 2032, due to the rising prevalence of allergic conditions, such as allergic rhinitis, allergic conjunctivitis, and asthma.

North America market was valued at USD 1.6 billion in 2023, due to growing awareness of conjunctivitis and its treatment options among healthcare professionals and the general population in the region.

AFT Pharmaceuticals, Ajanta Pharma Limited, Alembic Pharmaceuticals, Bausch & Lomb Incorporated, Cipla, Inc., JAWA Pharmaceuticals Pvt. Ltd., Novartis AG, NicOx SA, and Ocular Therapeutics, Inc., are some of the major conjunctivitis treatment companies worldwide.